CTOs on the Move

Psychemedics

www.psychemedics.com

 
Psychemedics (NASDAQ: PMD) is the world`s leading drug testing company using hair for the detection of drugs of abuse. Psychemedics has been successfully operating for 30 years and thousands of corporations worldwide currently rely on Psychemedics` patented hair analysis technology for their pre-employment and employee drug screening. Psychemedics` clients include over 10% of the Fortune 500, some of the largest police departments in America, Federal Reserve Banks, and schools.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Martin Curland
Vice President Information Technology and Chief Information Security Officer Profile

Similar Companies

Athenix

Athenix Corp. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TAU Systems

TAU Systems is a deep-tech company developing the first compact particle accelerators and specialized X-ray free-electron lasers that combine the capabilities of large accelerators with a small footprint to provide easy and affordable beam-time access for any company. Led by premier experts in laser-driven particle accelerators, TAU is democratizing access for the progress of biotechnology, nuclear and more.

NuProbe

NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world`s greatest challenges — non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capabilities in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings licensed by Wyss Institute, Harvard University.

NaturalNano Inc

NaturalNano Inc is a Pittsford, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MAIA Biotechnology

MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs